Semaglutide linked to lower bone fracture risk
In people with type 2 diabetes, semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared to other anti-obesity medications, according to a […]
In people with type 2 diabetes, semaglutide was associated with a 15% reduction in bone fractures and greater weight loss compared to other anti-obesity medications, according to a […]
New research has found that the use of GLP-1 receptor agonists*, a class of medications commonly prescribed for patients with obesity and diabetes, reduces the environmental footprint of […]
A new USC Schaeffer Center white paper finds expanded access to anti-obesity medications would lead to significant increases in life expectancy and disease-free years while generating a substantial societal return […]
Individuals treated with anti-obesity medications generally experience reduced appetite, which typically leads to reduced food intake. As a result, dietary quality becomes more important because nutritional needs must […]